Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Altea Therapeutics

Request full access

Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems

Atlanta, United StatesFounded 1998Biotech & Life Sciences

About Altea Therapeutics

Altea Therapeutics, founded in 1998 by Jonathan Eppstein, was a specialty pharmaceutical company focused on developing a novel transdermal drug delivery system. The company aimed to provide a painless and convenient alternative to injections for a wide range of medications. Altea secured significant venture capital, raising over $49.8 million from investors including Venrock and Domain Associates to fund its operations and research. The core of Altea's business was its proprietary PassPort® Transdermal Delivery System. This technology was designed to overcome the limitations of conventional patches, which can only deliver small, lipid-soluble molecules. The PassPort system utilized short bursts of focused thermal energy to create temporary, microscopic pores in the skin's outer layer. This enabled the delivery of large-molecule drugs like proteins, peptides, and vaccines, as well as water-soluble small molecules, directly into the body. The system offered the potential for controlled delivery, mimicking either a rapid injection or a slow drip, and aimed to improve patient compliance by eliminating the need for needles. The company's business model revolved around licensing its PassPort® technology to pharmaceutical partners for specific drugs. A major milestone was a 2009 agreement with Eli Lilly and Amylin Pharmaceuticals to develop a transdermal patch for Byetta, a drug for type 2 diabetes. This deal included upfront payments, potential milestones of up to $46 million, and royalties. Altea also had collaborations with other companies, such as Hospira, and was developing its own pipeline of products, including patches for insulin, pain management (fentanyl), and Parkinson's disease. Despite its promising technology and partnerships, Altea Therapeutics faced financial difficulties and ran out of capital. The company declared bankruptcy in December 2011, and its assets, including all patents and technology, were acquired by the Japanese materials manufacturer Nitto Denko in April 2012.

Source: Dealroom company data

At a glance

Founded
1998
Headquarters
Atlanta, United States
Sector
Biotech & Life Sciences

Altea Therapeutics in the Atlanta ecosystem

Live from Dealroom

The Altea Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Domain Associates

Series B and later1 investor entered at this stage

  • Aperture Venture Partners
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Atlanta HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Altea Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Altea Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.